22
Participants
Start Date
November 23, 2018
Primary Completion Date
March 3, 2021
Study Completion Date
February 23, 2022
Durvalumab (MEDI4736)
Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.
Tremelimumab
Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles
Sterotactic body radiation therapy (SBRT)
delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
Radiofrequency ablation (RFA)
performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
Medical University Vienna - General Hospital AKH, Vienna
Institut Bergonie, Bordeaux
Universitaetsklinikum Carl Gustav Carus, Dresden
Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden, Leipzig
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam
Radboud University Medical Center Nijmegen, Nijmegen
Karolinska University Hospital - Karolinska Institutet - Danderyds Hospital, Stockholm
Inselspital, Bern
Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie, Geneva
UniversitaetsSpital Zurich, Zurich
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK